

Pablo Umana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1535951/publications.pdf>

Version: 2024-02-01

40
papers

3,893
citations

236925

25
h-index

330143

37
g-index

41
all docs

41
docs citations

41
times ranked

5403
citing authors

#	ARTICLE	IF	CITATIONS
1	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. , 2022, 10, e003766.		15
2	Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics, 2022, 12, 1373-1387.	10.0	12
3	Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Advances, 2022, 6, 1025-1037.	5.2	25
4	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology, 2022, 11, 2039432.	4.6	14
5	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN γ /CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS ONE, 2021, 16, e0241091.	2.5	22
6	Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. Oncoimmunology, 2021, 10, 1869389.	4.6	14
7	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Journal of Clinical Oncology, 2021, 39, 1959-1970.	1.6	228
8	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14
9	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood, 2021, 138, 2655-2669.	1.4	43
10	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs, 2021, 13, 1913791.	5.2	53
11	Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid. Pharmaceutics, 2021, 13, 2105.	4.5	4
12	Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Frontiers in Oncology, 2020, 10, 575737.	2.8	28
13	CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. MAbs, 2020, 12, 1840709.	5.2	1
14	The PET-Tracer ^{89}Zr -Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. Cancer Research, 2020, 80, 2903-2913.	0.9	30
15	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine, 2020, 12, .	12.4	229
16	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
17	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nature Communications, 2020, 11, 3196.	12.8	43
18	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Engineering, Design and Selection, 2019, 32, 207-218.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	178
20	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019, 154, 21-31.	3.8	89
21	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 4785-4797.	7.0	146
22	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. <i>Journal of Autoimmunity</i> , 2018, 95, 1-14.	6.5	129
23	p95HER2â€™T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	59
24	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>Oncolmmunology</i> , 2017, 6, e1277306.	4.6	190
25	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer Cell</i> , 2017, 31, 396-410.	16.8	251
26	Combination therapy with the type II anti-CD20 antibody obinutuzumab. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1145-1162.	4.1	6
27	A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 129-140.	4.2	112
28	Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. <i>Journal of Immunotherapy</i> , 2016, 39, 279-289.	2.4	28
29	<i>In Vivo</i> Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cellâ€™Mediated Tumor Killing. <i>Clinical Cancer Research</i> , 2016, 22, 4417-4427.	7.0	58
30	Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 457-466.	2.1	226
31	CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. <i>Oncolmmunology</i> , 2016, 5, e1203498.	4.6	94
32	RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 946-957.	4.1	99
33	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3286-3297.	7.0	260
34	CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. <i>Blood</i> , 2016, 128, 1836-1836.	1.4	22
35	Sustained <i>in vivo</i> signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>Journal of Autoimmunity</i> , 2015, 56, 66-80.	6.5	87
36	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Antiâ€™Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , 2015, 56, 778-783.	5.0	84

#	ARTICLE	IF	CITATIONS
37	Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2151-5160.	1.3	44
38	Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity. <i>Journal of Immunology</i> , 2014, 192, 2252-2260.	0.8	127
39	GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibodyâ€™Response. <i>Clinical Cancer Research</i> , 2014, 20, 1055-1055.	7.0	3
40	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellâ€™mediated B-cell cytotoxicity. <i>Blood</i> , 2010, 115, 4393-4402.	1.4	782